{"filings":[{"id":554160,"accession_number":"0001193125-26-232524","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2026-05-20T20:01:49+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Inovio stockholders elect eight directors, approve omnibus plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected; votes for ranged from 22.3M to 22.7M, with 17.1M broker non-votes.","Ratification of Ernst & Young as auditor for 2026 approved: 39.3M for, 1.2M against, 143k abstain.","Non-binding advisory vote on NEO compensation passed with 21.5M for, 1.6M against, 471k abstain.","Amendment and restatement of 2023 Omnibus Incentive Plan approved with 21.6M for, 1.5M against.","Board adopted bylaw amendment establishing Lead Independent Director role and clarifying Chairman duties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68084,"accession_number":"0001055726-26-000019","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2026-05-13T20:07:44+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio Q1 net loss $19.7M ($0.28/shr); cash runway into Q1 2027 beyond Oct PDUFA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.7M, flat YoY; diluted EPS ($0.28) vs ($0.51) due to fewer shares.","Revenue not reported (pre-revenue biotech); R&D spend $14.1M (-12% YoY), G&A $7.9M (-12%).","Cash & equivalents $37.7M at Mar 31, plus $16M from April offering; expects ops into Q1 2027.","FDA reviewing INO-3107 BLA under accelerated approval; PDUFA date Oct 30, 2026.","Collaboration with Akeso to test INO-5412 + cadonilimab in GBM in Dana-Farber INSIGhT trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90953,"accession_number":"0001193125-26-142885","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Inovio prices $17.5M public offering of 12.5M shares and warrants; net proceeds ~$16M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["12.5M shares and Series A/B warrants (each exercisable for 1 share at $1.40) priced at $1.40 per unit.","Gross proceeds $17.5M; net proceeds ~$16M after underwriting discounts and expenses.","Underwriters granted 30-day option to buy up to 1.875M additional shares and warrants.","Series A warrants expire in 1 year, Series B warrants in 5 years; beneficial ownership cap 4.99%.","Closing expected April 6, 2026; Piper Sandler sole book-running manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90952,"accession_number":"0001193125-26-138870","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Inovio suspends ATM prospectus; raised $3.2M from 1.3M shares under program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On April 1, 2026, Inovio notified Oppenheimer of suspension and termination of the ATM prospectus from August 13, 2024.","No further sales under the ATM program until a new prospectus is filed; the Sales Agreement remains in effect.","As of April 1, 2026, Inovio had sold 1,319,644 shares for gross proceeds of $3.2 million under the ATM program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100816,"accession_number":"0001055726-26-000009","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio reports FY 2025 net loss $84.9M; INO-3107 BLA accepted with PDUFA Oct 30, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net income $3.8M ($0.06 basic EPS) mainly from $21.2M non-cash warrant gain; FY net loss $84.9M ($1.81/share).","Cash, equivalents & short-term investments $58.5M as of Dec 31, 2025; estimated runway into Q4 2026 with Q1 2026 burn ~$22M.","FDA accepted BLA for INO-3107 under accelerated approval program; PDUFA date Oct 30, 2026; FDA questioned accelerated eligibility.","Published INO-3107 Phase 1/2 and long-term data in Nature Communications and The Laryngoscope showing reduced surgeries.","Entered clinical trial collaboration with Akeso to evaluate INO-5412 + cadonilimab for glioblastoma in Dana-Farber INSIGhT trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100815,"accession_number":"0001193125-26-024431","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Inovio extends Series A Warrant expiration to March 31, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment extends expiration of Series A Warrants (up to 13,564,268 shares) from Jan 28, 2026 to March 31, 2026.","Warrants issued in July 2025 public offering; exercise price $1.75/share (pre-funded at $0.001).","Original expiration was 30 days after FDA BLA acceptance for INO-3107; extension provides additional exercise window.","All other warrant terms remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117118,"accession_number":"0001193125-25-332322","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA accepts INOVIO's BLA for INO-3107; standard review, PDUFA Oct 2026, but flags accelerated approval issue","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BLA accepted for review; FDA classified as standard; no advisory committee planned.","PDUFA goal date October 30, 2026.","FDA preliminary conclusion: inadequate info to justify accelerated approval eligibility.","Company to request meeting with FDA to discuss accelerated approval; not pursuing traditional pathway.","INO-3107 is investigational immunotherapy for recurrent respiratory papillomatosis (RRP) in adults."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117117,"accession_number":"0001193125-25-275721","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Inovio prices 15.1M share offering at $1.90, net proceeds ~$26.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Inovio sold 13.158M shares at $1.90; underwriters exercised option for 1.974M additional shares.","Net proceeds expected ~$26.5M after discounts and expenses; closing November 12, 2025.","Piper Sandler & Co. acted as sole book-running manager for the offering.","Offering made under effective shelf registration statement; all shares sold by Inovio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117116,"accession_number":"0001055726-25-000064","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"INOVIO completes rolling BLA for INO-3107; Q3 net loss $45.5M, cash runway into Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed rolling BLA submission for INO-3107 (RRP); priority review requested; potential FDA decision mid-2026.","Net loss of $45.5M ($0.87/share) versus $25.2M loss a year ago; operating loss improved to $21.2M from $27.3M.","Cash and short-term investments $50.8M as of Sept 30, 2025; estimated runway into Q2 2026 with Q4 cash burn ~$22M.","R&D expenses fell to $13.3M from $18.7M; G&A expenses $7.9M down from $8.6M year-over-year.","Phase 1 DMAb data for COVID-19 published in Nature Medicine; demonstrated durable antibody expression in humans."],"consensus_eps_estimate":-0.4274,"consensus_eps_actual":-2.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":65343.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133567,"accession_number":"0001055726-25-000056","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio Q2 net loss narrows to $23.5M; BLA for INO-3107 on track for 2H25 submission","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.5M ($0.61/share) vs $32.2M ($1.19/share) YoY; total operating expenses $23.1M down from $33.3M.","Completed CELLECTRA 5PSP device DV testing; requested rolling BLA submission for INO-3107 by year end.","Cash, cash equivalents, and short-term investments $47.5M at June 30; plus $22.5M from July offering, supporting ops into Q2 2026.","Long-term INO-3107 data published: 86% of patients had 50-100% reduction in surgeries by Year 2; mean surgeries reduced from 4.1 to 0.9.","R&D expenses fell to $14.5M from $23.1M, reflecting lower drug manufacturing and clinical costs."],"consensus_eps_estimate":-0.6153,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":65343.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133566,"accession_number":"0001193125-25-155830","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Inovio prices $25M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $25M from 14,285,715 shares and accompanying Series A/B warrants at $1.75/unit.","Net proceeds expected ~$22.5M after underwriting discounts and expenses; closing on July 7, 2025.","Underwriters have 30-day option for up to 2,142,857 additional shares and warrants.","Series A warrants expire 12 months from issuance or 30 days after FDA acceptance of BLA for INO-3107.","Series B warrants expire 5 years; Piper Sandler sole book-runner, Oppenheimer passive bookrunner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150244,"accession_number":"0001055726-25-000045","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Inovio shareholders elect eight directors, ratify auditor, approve executive compensation and equity plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Eight directors elected: each received 7.3M-8.4M votes for, 0.6M-1.7M withheld, 11M broker non-votes.","Ernst & Young ratified as auditor for FY2025: 19.3M for, 0.6M against, 0.2M abstain.","Advisory say-on-pay passed: 7.9M for, 1.1M against, 0.2M abstain, 11M broker non-votes.","Amendment and restatement of 2023 Omnibus Incentive Plan approved: 7.8M for, 1.2M against, 0.1M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150243,"accession_number":"0001055726-25-000027","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio Q1 net loss narrows to $19.7M; BLA submission for INO-3107 on track for mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $19.7M ($0.51/share) from $30.5M ($1.31) in Q1 2024.","Cash and short-term investments $68.4M as of Mar 31, 2025, down from $94.1M at Dec 31, 2024.","On track to begin rolling BLA submission for INO-3107 (RRP) in mid-2025; FDA acceptance targeted by year-end.","DMAb Phase 1 trial: 100% of participants (24/24) at week 72 maintained antibody levels; no anti-drug antibodies.","R&D expenses decreased to $16.1M from $20.9M; net cash burn guidance ~$22M for Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":65343.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169252,"accession_number":"0001055726-25-000013","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio reports FY2024 net loss $107.3M; on track for INO-3107 BLA submission mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.4M Q4 ($0.65/share) and $107.3M FY ($3.95/share), narrower than 2023's $135.1M.","Cash, equivalents & investments $94.1M at Dec 31, 2024, down from $145.3M at Dec 31, 2023.","BLA for INO-3107 (RRP) on track for rolling submission mid-2025; device verification testing complete H1 2025.","DMAb interim data: 100% of participants (24/24) maintained antibody levels at week 72; no anti-drug antibodies.","Raised >$72M from ATM and two equity offerings in 2024; cash runway into Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186289,"accession_number":"0001193125-24-279061","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Inovio prices $30M public offering of 10M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["10M shares at $3.00/share plus warrants to buy 10M shares at $3.76, 5-year term.","Gross proceeds $30M; net proceeds ~$27.6M after discounts and expenses.","Closing expected December 16, 2024, subject to customary conditions.","Warrants include 4.99% beneficial ownership limitation (up to 9.99% on election).","Oppenheimer & Co. and Citizens JMP joint book-runners; Stephens Inc. lead manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186288,"accession_number":"0001055726-24-000053","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio Q3 net loss $25.2M; INO-3107 BLA on track for mid-2025 submission","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.2M ($0.89/share) vs $33.9M loss in Q3 2023; R&D expense $18.7M, G&A $8.6M.","Cash, equivalents and short-term investments $84.8M at Sept 30, 2024; cash runway into Q3 2025.","INO-3107 Phase 1/2 data: 81% of 32 patients had fewer surgeries; 28% had zero surgeries post-treatment.","All non-device BLA modules for INO-3107 on track for completion by year-end 2024; BLA submission targeted mid-2025.","Advancing Phase 3 plan for INO-3112 in HPV+ throat cancer; Phase 2 Ebola vaccine booster trial in FDA discussions."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":100762.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202911,"accession_number":"0001193125-24-199331","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"INOVIO enters $60M at-the-market equity distribution agreement with Oppenheimer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales agreement enables INOVIO to sell up to $60M of common stock via Oppenheimer as agent.","Commission of up to 3% of gross proceeds; INOVIO may suspend or terminate offering at any time.","Shares sold under existing S-3 registration statement; proceeds for general corporate purposes.","No obligation to sell any shares; sales are at INOVIO's sole discretion and subject to market conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202910,"accession_number":"0001193125-24-197065","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio Q2 net loss $32.2M; INO-3107 BLA submission delayed to mid-2025 due to device manufacturing issue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $32.2M ($1.19/share) vs $35.5M ($1.61/share) in Q2 2023; revenue not disclosed.","Cash, equivalents and short-term investments $110.4M; cash runway estimated into Q3 2025.","BLA submission for lead candidate INO-3107 (RRP) delayed to mid-2025 due to manufacturing issue with disposable device component.","Appointed Steve Egge as Chief Commercial Officer; submitted Phase 3 trial design for INO-3112 to European regulators.","Raised $33.2M net in April 2024 stock/warrant offering."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":100762.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219115,"accession_number":"0001193125-24-148076","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Inovio grants performance-based RSUs tied to INO-3107 milestones; stockholders re-elect board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Shea receives 33,200 target PSUs; CFO Kies and CSO Humeau each receive 8,900 target PSUs.","Up to 70% of PSUs vest on INO-3107 milestones (FDA approval, launch, market share, sales) by 2025-2027.","Remaining 30% vest on relative TSR vs. Russell 2000 Biotech index June 2024-Dec 2027 (50%-150% of target).","Stockholders ratified Ernst & Young as auditor (11.1M for) and approved non-binding say-on-pay (3.0M for).","All eight director nominees elected with votes ranging 3.1M-3.8M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219114,"accession_number":"0001193125-24-137228","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio Q1 net loss narrows to $30.5M; BLA for INO-3107 on track for H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["BLA submission for INO-3107 (recurrent respiratory papillomatosis) on track for H2 2024 under accelerated approval pathway.","Phase 3 trial of INO-3112 + LOQTORZI for HPV-related throat cancer advancing; FDA feedback received.","Net loss $30.5M ($1.31/sh) vs $40.6M ($1.89/sh) in Q1 2023; R&D expenses fell to $20.9M.","Cash & equivalents $105.6M at Mar 31, 2024; April offering raised net ~$33.2M; cash runway into Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219113,"accession_number":"0001193125-24-099067","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Inovio priced ~$36M underwritten offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 2,536,258 shares at $7.693/share and pre-funded warrants for 2,135,477 shares at $7.692/warrant.","Gross proceeds ~$36M; net proceeds ~$33.2M after underwriting discounts and expenses.","Offering led by Deep Track Capital; closes on or about April 18, 2024.","Oppenheimer & Co. and Citizens JMP Securities acting as joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}